Immuneering Management

Management criteria checks 2/4

Immuneering's CEO is Ben Zeskind, appointed in Feb 2008, has a tenure of 16.17 years. total yearly compensation is $2.05M, comprised of 27.8% salary and 72.2% bonuses, including company stock and options. directly owns 10.85% of the company’s shares, worth $5.18M. The average tenure of the management team and the board of directors is 2.6 years and 3.2 years respectively.

Key information

Ben Zeskind

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage	27.8%
CEO tenure	16.2yrs
CEO ownership	10.8%
Management average tenure	2.6yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ben Zeskind's remuneration changed compared to Immuneering's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$53m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$570k	-US$51m
Sep 30 2022	n/a	n/a	-US$48m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$400k	-US$34m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$806k	US$293k	-US$17m

Compensation vs Market: Ben's total compensation ($USD2.05M) is above average for companies of similar size in the US market ($USD667.11K).

Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.

CEO

Ben Zeskind (41 yo)

16.2yrs

Tenure

US$2,054,966

Compensation

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Benjamin Zeskind	Co-Founder	16.2yrs	US$2.05m	10.85% $ 5.2m
Robert Carpenter	Co-Founder & Chair Emeritus	16.3yrs	US$136.78k	3.92% $ 1.9m
Brett Hall	Chief Scientific Officer	4.4yrs	US$1.36m	1.18% $ 563.8k
Mallory Morales	Principal Financial & Accounting Officer	1.7yrs	no data	0.028% $ 13.5k
Paula George	Director of Accounting & Operations and Assistant Corporate Controller	2.6yrs	no data	no data
Michael Bookman	Chief Legal Officer & Secretary	2.8yrs	no data	0.013% $ 6.3k
Leah Neufeld	Chief People Officer	1.5yrs	no data	0.034% $ 16.3k
Peter King	Head of Discovery & VP	no data	no data	no data
Praveen Nair	Head of Translational Pharmacology & VP	2.1yrs	no data	no data
Harold Brakewood	Chief Business Officer	1.1yrs	no data	0.013% $ 6.4k
Stephen Sebastian	Executive Director & Corporate Controller	2.6yrs	no data	no data

2.6yrs

Average Tenure

51yo

Average Age

Experienced Management: IMRX's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Benjamin Zeskind	Co-Founder	16.2yrs	US$2.05m	10.85% $ 5.2m
Robert Carpenter	Co-Founder & Chair Emeritus	14.9yrs	US$136.78k	3.92% $ 1.9m
Laurie Keating	Independent Director	3.1yrs	US$106.11k	0.048% $ 22.8k
Douglas Lauffenburger	Co-Chairman of Scientific Advisory Board	no data	no data	no data
Peter Feinberg	Director	3.3yrs	US$88.61k	3.74% $ 1.8m
Ann Berman	Independent Chair	2.8yrs	US$107.61k	0.23% $ 110.0k
Diana Hausman	Independent Director	2.3yrs	US$323.49k	0% $ 0
Max Artyomov	Co-Chairman of Scientific Advisory Board	no data	no data	no data
Bijan Nejadnik	Member of Scientific Advisory Board	no data	no data	no data
Tanios Bekaii-Saab	Member of Scientific Advisory Board	no data	no data	no data
Daniel Ahn	Member of Scientific Advisory Board	no data	no data	no data
Denis Guttridge	Member of Scientific Advisory Board	no data	no data	no data

3.2yrs

Average Tenure

61yo

Average Age

Experienced Board: IMRX's board of directors are considered experienced (3.2 years average tenure).

Immuneering Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Chair recently bought US$123k worth of stock

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering Corporation Announces Committee Changes

Recent updates

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age